Nordiske forskningsperspektiver på arbejdsmiljø : Mening, indflydelse og samarbejde

Indflydelse, samarbejde og mening i arbejdet. De særlige træk ved det nordiske arbejdsmarked bygger på, at arbejdsgivere og fagbevægelse tidligt har anerkendt hinanden. Samarbejdet har været afsæt for de forskningsprojekter og forsøg med udvikling af arbejdsorganiseringen med en høj grad af indflydelse for medarbejderne. Den nordiske forskningstradition har opfattet medarbejderne som aktivt og kollektivt handlende og har fokuseret på sammenhængen mellem arbejdsopgaven og fællesskabet – i modsætning til de individuelle teoriers fokus på motivation og selvudvikling. Forfatterne ser et behov for at revitalisere den nordiske forskningstradition og bringe den i spil i forhold til ny teknologi og globalisering. Derigennem kan forskningen bidrage til et bæredygtigt arbejdsmarked, som er sundt, udviklende og produktivt, så nordiske virksomheder kan klare sig i den internationale konkurrence

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated. METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population at high CV risk. The primary efficacy end point is a composite of time to CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Data are systematically collected for safety outcomes, including hypoglycemia, pancreatitis, and malignancy. RESULTS: Enrollment began in July 2010 and ended in August 2013; 6,068 patients from 49 countries were randomized. Of these, 69% are men and 75% are white; at baseline, the mean ± SD age was 60.3 ± 9.7 years, body mass index was 30.2 ± 5.7 kg/m(2), and duration of T2DM was 9.3 ± 8.2 years. The qualifying ACS was a myocardial infarction in 83% and unstable angina in 17%. The study will continue until the positive adjudication of the protocol-specified number of primary CV events. CONCLUSION: ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk